课题基金 / 基金详情

Functional Dissection of the K27M Histone Mutation In Gliomagenesis

Functional Dissection of the K27M Histone Mutation In Gliomagenesis
胶质瘤发生中 K27M 组蛋白突变的功能剖析
批准号:
10581204
负责人:
Oren Josh Becher
金额:
$17.69万
依托单位国家:
美国
项目类别:
财政年份:
2022
资助国家:
美国
项目状态:
已结题
起止时间:
2022-03-01 至 2023-08-31

项目摘要

项目成果

Oren Josh Becher的其他基金

相似基金

相关文献

中文摘要
翻译
点击翻译按钮获取中文摘要
英文摘要
Diffuse Intrinsic Pontine Glioma (DIPG) is a rare pediatric brain tumor for which no cure or efficacious therapies exist. Recently, novel mutations in ACVR1, a BMP pathway receptor, were discovered that commonly co-occur with a K27M mutation in the gene encoding histone H3.1 (H3.1 K27M) in DIPG patient samples. The overall objectives of this proposal are to identify the mechanisms by which mutant ACVR1 and H3.1 K27M contribute to DIPG pathogenesis and to uncover strategies to pharmacologically target these mutations or downstream signaling molecules. Our central hypothesis is that mutant ACVR1 and H3.1 K27M contribute to brainstem gliomagenesis by activating the Stat3 and Notch signaling pathways, respectively. We plan to use novel genetically engineered mouse models representing primary tumors growing in their native microenvironment to interrogate the effects of both mutant ACVR1 and H3.1 K27M on gliomagenesis, proliferation, apoptosis, cell differentiation, self- renewal, cell motility, and angiogenesis in vitro and in vivo. We will also use both genetic and pharmacologic tools to determine the contributions of Stat3 and Notch to ACVR1-mediated functions and to H3.1 K27M-mediated functions, respectively. Finally, we will test a panel of ACVR1, Stat3, and Notch inhibitors in vitro and in vivo in both human and murine DIPG models. Once it is understood how ACVR1 mutations and H3.1 K27M contribute to DIPG pathogenesis, the relevant developmental pathways can be manipulated pharmacologically, resulting in new and innovative therapeutic approaches that are based upon the basic biology inherent, and specific, to DIPG. We anticipate these outcomes will have a positive impact by 1) laying the foundation for future pre-clinical and clinical trials for DIPG, 2) characterizing the first genetically engineered mouse models of DIPG driven by mutant ACVR1 and H3.1 K27M, and 3) advancing our understanding of signaling pathway activities that are essential for DIPG growth.
期刊论文(5)
专著(0)
科研奖励(0)
会议论文
DOI: 10.1002/glia.24189
发表时间: 2022-09
期刊: Glia
影响因子: 6.2
作者: []
通讯作者:
DOI: 10.1093/neuros/nyaa301
发表时间: 2020-07
期刊: Neurosurgery
影响因子: 4.8
作者: [Takahiro Sasaki;H. Katagi;S. Goldman;O. Becher;R. Hashizume]
通讯作者: Takahiro Sasaki;H. Katagi;S. Goldman;O. Becher;R. Hashizume
A new path to alternative lengthening of telomeres?
端粒替代延长的新途径?
DOI: 10.1093/neuonc/noad054
发表时间: 2023
期刊: Neuro-oncology
影响因子: 15.9
作者: [Becher,OrenJ]
通讯作者: Becher,OrenJ
DOI: 10.3389/fonc.2018.00191
发表时间: 2018
期刊: Frontiers in oncology
影响因子: 4.7
作者: [Hoeman C, Shen C, Becher OJ]
通讯作者: Becher OJ
The role of Myeloid cells in pediatric-high grade gliomas
The role of Myeloid cells in pediatric-high grade gliomas
Role of the K27M histone mutation in midline gliomas initiated in oligodendrocyte progenitors
Functional Dissection of the K27M Histone Mutation in Vivo
海外基金